Viatris (VTRS) Capital Expenditures Growth (1y) (2021 - 2026)
Viatris (VTRS) Capital Expenditures Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.87 Bn | 42.91 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.21 Bn | 39.55 Bn | 2.15 Bn | 8.33% |
| 3 | Zoetis | 31.48 Bn | 29.80 Bn | 1.05 Bn | -19.86% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -1.95% |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | 73.63% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -0.19% |
| 7 | Neurocrine Biosciences | 15.49 Bn | 15.10 Bn | 935.80 Mn | -37.60% |
| 8 | Elanco Animal Health | 11.70 Bn | 11.17 Bn | 798.00 Mn | -42.11% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.11 Bn | 7.46 Bn | 397.90 Mn | -37.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.19% |
| Mar 31, 2026 | -6.34% |
| Dec 31, 2025 | 39.96% |
| Sep 30, 2025 | 12.73% |
| Jun 30, 2025 | -10.03% |
| Mar 31, 2025 | -14.46% |
| Dec 31, 2024 | -15.17% |
| Sep 30, 2024 | -19.71% |
| Jun 30, 2024 | -13.27% |
| Mar 31, 2024 | 4.18% |
| Dec 31, 2023 | 7.68% |
| Sep 30, 2023 | -7.70% |
| Jun 30, 2023 | -19.19% |
| Mar 31, 2023 | -25.89% |
| Dec 31, 2022 | -22.14% |
| Sep 30, 2022 | -14.13% |
| Jun 30, 2022 | -6.05% |
| Mar 31, 2022 | 30.30% |
| Dec 31, 2021 | 68.86% |
| Mar 31, 2021 | 14.06% |